In the bone marrow (BM), Wnt proteins activate the betacatenin pathway and the non-obese severe combined immunodeficient (NOD-SCID)-repopulating capacity of normal haematopoietic stem cells. They lead to increased expression of HOXB4 and NOTCH1 implicated in the self-renewal of haematopoietic stem cells . Up-regulation of the beta-catenin pathway has been suggested in chronic myeloid leukaemia (CML)-derived granulocyte-macrophage progenitor cells (GMPs) and multiple myeloma (MM) cells (Derksen et al, 2004; Jamieson et al, 2004) . Furthermore, betacatenin reportedly plays a significant role in promoting cell proliferation, adhesion, and survival in vitro (Chung et al, 2002) . The expression of beta-catenin is also enhanced by oncogenic FLT3 signals and associated with poor prognosis (Tickenbrock et al, 2005; Ysebaert et al, 2006) . However, there are some contradictory reports. Studies of conditional knockout mice with a beta-catenin gene (Ctnnb1) deletion indicated that Ctnnb1 is not indispensable for haematopoiesis (Cobas et al, 2004) . Furthermore, an active form of Ctnnb1 compromised haematopoietic stem cell maintenance and blocked differentiation in transgenic mice experiments (Simon et al, 2005) . The role of the Wnt/beta-catenin pathway in malignant haematopoiesis therefore needs to be further elucidated.
According to previous studies, the expression of beta-catenin is associated with activation of the Wnt pathway as well as poor prognosis (Tickenbrock et al, 2005; Ysebaert et al, 2006) . However, beta-catenin is associated not only with Wnt signaling but also with adherence junctions (Conacci-Sorrell et al, 2002) . It is anchored to the cell inner surface membrane via cadherins. In normal bone marrow (BM), the vascular endothelium expresses a significantly higher amount of beta-catenin relative to the level in haematopoietic cells. Accordingly, immunohistochemical detection of nuclear NPBC would enable a better understanding of the role of beta-catenin in leukaemia.
This study investigated the subcellular localization of betacatenin in BM specimens from acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients using two anti-beta-catenin antibodies: one against C-terminal peptides and another against N-terminal non-phosphorylated peptides. The latter antibody detected nuclear NPBC, and positive staining for nuclear NPBC was associated with particular clinical characteristics of AML and MDS.
Materials and methods

Patient samples
For clinical samples, BM clots were obtained during routine diagnostic procedures. Beta-catenin expression was analyzed in BM specimens from patients newly diagnosed at the Nagoya University Hospital between 2000 and 2006 (Table I ). The de novo AML patients consisted of 35 men and 19 women with a median age of 53 years (range, 20-81 years), and FLT3 mutations were detected in seven of 22 patients with AML (31AE8%). The MDS patients consisted of 28 men and 16 women with a median age of 57 years (range, 22-89 years) . BM mononuclear cells were harvested by standard Ficoll/Paque density gradient centrifugation (Amersham Pharmacia Biosciences, Roozendaal, the Netherlands), and were suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 IU/ml of penicillin G and 100 lg/ml of streptomycin.
Antibodies
For immunohistochemical and immunoblot studies, two monoclonal antibodies were used; one was against C-terminal peptides (clone14, IgG1; BD Transduction Laboratories/Life Science Research, Heidelberg, Germany), enabling recognition of pan beta-catenin (PBC), and the other was against 
Immunohistochemical staining
Samples were fixed with ice-cold 4% paraformaldehyde for 16-24 h, embedded in paraffin, sectioned transversely (thickness, 3 lm), and processed for immunohistochemistry to determine the localization of beta-catenin. After removal of paraffin with xylene and dehydration with a series of ethanol solutions, the tissue sections were subjected to microwave irradiation (750 W) for 15 min in 0AE01 mol/l citrate buffer (pH 6AE0). The sections were then placed in an automated immunostainer (Ventana Medical Systems, Tucson, AZ, USA) as described (Xu et al, 2002) . For negative controls, primary antibodies were replaced with mouse IgG. The subcellular distribution of beta-catenin (i.e. restriction to the nucleus or presence in the membrane) was assessed without knowledge of the French-America-British (FAB) subtypes, FLT3 mutations or karyotypes. We investigated a single case twice for NPBC expression. The entire section was screened to find the region with the highest immunostaining.
The score was determined in each case after counting at least 500 nuclei in 3-5 randomly selected regions. When 20% or more of the BM mononuclear cells were positive for nuclear staining of NPBC, they were classified as nuclear NPBC + . The cut-off value of 20% was determined by the median distribution of the percentage of BM mononuclear cells stained by NPBC. As described in the results, some erythroblasts were positive for NPBC but the number was <20% except in the case of M6 patients. On the other hand, almost all blasts in M7 and other cases tested positive. The discrimination of cell types based on the 20% criterion therefore enabled a clear delineation.
Immunoblotting
Cell lysates from AML cells were extracted as previously described (Ozeki et al, 2004) . A total of 1 · 10 6 cells were directly lysed in sample buffer and then subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis on a 10% gel, and the separated proteins were transferred to a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA). The membrane was initially incubated at room temperature for 1 h with 5% nonfat milk and 0AE1% Tween-20 in Tris-buffered saline and then overnight with mouse monoclonal antibodies at a 1:2000 dilution in the same solution. After washing, the membrane was incubated for 1 h with a 1:5000 dilution of horseradish peroxidase-conjugated mouse antibodies to mouse IgG (MBL, Amersham, Bucks, UK), and immune complexes were then detected with enhanced chemiluminescence (ECL) reagents (Amersham).
Statistical analysis
The v 2 test was used to calculate the difference of frequencies between nuclear NPBC + and NPBC ) groups. The MannWhitney U-test was used to compare continuous variables. Kaplan-Meier curves were drawn using statview software (Macintosh; SAS Institute, Cary, NC, USA). P-values <0AE05 were considered significant.
Results
Using an anti-beta-catenin C-terminal peptide antibody, betacatenin was stained in the membrane and cytoplasm of erythroid cells from normal BM. In de novo AML specimens, significant staining was observed only in M6. This antibody also detected BM vessels whose density was increased in AML specimens as previously reported (Serinsöz et al, 2004 ; Fig 1A) . On the other hand, an anti-N-terminal nonphosphorylated peptide antibody gave no significant staining in the normal BM. In AML specimens, nuclear NPBC was detected in erythroid blasts, megakaryoblasts and some myeloblasts ( Fig 1A) . In M6 specimens, nuclear NPBC was detected in 30-80% of myelomonocytic cells and nearly 100% of erythroblastic cells (Fig 1A) . In M7 specimens, megakaryocytes were also strongly positive for nuclear NPBC (Fig 1A) . In total, 20% or more of the BM mononuclear cells were positive for nuclear NPBC in 22 (40AE7%) of 54 AML patients (Table I , Fig 1B) . There was a strong male predominance of nuclear NPBC + cases, comprising 81AE8% (18/22) in AML patients (Table I) . However, the reason for this is unclear. In our cohort study, the karyotypes of female patients correlated to t(8;21)/t(15;17), which did not express nuclear NPBC. Thus the small numbers of studied patients seem to give some bias to the male predominance. A large-scale study is necessary to confirm this association. Nuclear NPBC + staining was closely associated with AML subtype: it occurred frequently (8/9) in M6 and M7 and rarely (0/7) in M3 ( Fig 1B) , and nuclear NPBC + was preferentially detected in erythroid and megakaryoblastic leukaemia compared to other myeloid leukaemias (M6-M7 vs. M0-M5, P < 0AE001). In MDS specimens, erythroid cells and endothelial cells were stained with the anti-beta-catenin C-terminal peptide antibody (Fig 2A) . As observed for AML specimens, the cytoplasm and inner membrane were stained by this antibody. The anti-betacatenin N-terminal nonphosphorylated peptide antibody detected nuclear staining in myeloblasts and erythroblasts that was similar to the pattern seen in AML cases (Fig 2A) . Nuclear NPBC was found in 18 (40AE9%) of 44 MDS patients, and was related to the FAB classification of MDS (Table I , Fig 2B) . Nuclear NPBC + was preferentially detected in refractory anaemia with excess blasts in transformation (RAEBT) compared to other MDS subtypes [RAEBT versus refractory anaemia (RA)/refractory anaemia with ringed sideroblasts (RARS)/RAEB, P = 0AE01].
To confirm whether these two antibodies recognized betacatenin, a total of 41 samples from AML and MDS patients were subjected to immunoblot analysis. The anti-beta-catenin C-terminal peptide antibody detected bands at a molecular weight of 95 kDa, corresponding to beta-catenin, in most samples except for M3 (Fig 3A) . The anti-N-terminal nonphosphorylated peptide antibody gave bands of the same size in only a few samples of AML and MDS (Fig 3B) . The results of immunoblotting corresponded to those of immunostaining, although the latter was more sensitive than the former.
The above findings suggest that expression of nuclear NPBC could be used to identify some subsets of AML and MDS. Next we studied whether nuclear NPBC was associated with chromosomal abnormalities or genetic alterations. Previous studies suggested that AML-associated translocations, such as t(8;21) and t(15;17), contributed to the activation of gammacatenin, or that FLT3 mutation might be associated with the stabilization of beta-catenin. In this study, however, nuclear NPBC was never detected in AML with t(8;21) or t(15;17). In AML/MDS with )7/)7q and a complex karyotype, nuclear NPBC was frequently detected (P = 0AE007 and P = 0AE02, respectively; Table II ). Moreover, detection was not related to FLT3 internal tandem duplication (ITD ; Table II) .
Finally, we studied whether clinical characteristics and outcome were different between nuclear NPBC + and NPBC ) AML patients. NPBC + AML patients showed significantly lower hemoglobin levels, lower blast percentages in the BM, and lower CR rates (Table I ). There were no significant differences between the NPBC + and NPBC ) groups in the MDS patients (Table I) . However, nuclear NPBC was associated with a high International Prognostic Scoring System (IPSS) score (Table I) . Of note, nuclear NPBC + AML patients had worse overall survival than NPBC ) AML patients (Fig 4A) .
Even if the M6/M7 subtype and/or M3 subtype was excluded from the analysis, there was still a significant association between nuclear NPBC + and survival (Fig 4B-D) .
Discussion
This study used nuclear NPBC as a biomarker for the activated Wnt/beta-catenin signaling pathway. The anti-beta-catenin C-terminal peptide antibody detected total beta-catenin in immunoblots but mainly cytoplasmic and membrane-associated beta-catenin in immunohistological analysis, whereas the anti-beta-catenin N-terminal nonphospholylated peptide antibody detected only nuclear beta-catenin in both analyses (data not shown). Accordingly, it was concluded that the nuclear staining with the latter antibody identified nuclear nonphosphorylated beta-catenin. Nuclear NPBC was detected in 22 (40AE7%) of 54 AML patients and 18 (40AE9%) of 44 MDS patients. Positive staining of nuclear NPBC was associated with particular AML subtypes (M6 and M7), a low complete remission rate, and poor prognosis. The presence of nuclear NPBC was also associated with a high IPSS score of MDS and with )7/)7q and complex karyotypes.
Previous reports indicated that a significant proportion of AML samples expressed beta-catenin on immunoblot analysis.
The expression of beta-catenin is related to CD34 expression, poor prognosis and clonogenic capacity ex vivo (Ysebaert et al, 2006) . Furthermore, beta-catenin is expressed in normal CD34 + progenitor cells and the expression level is reduced upon differentiation (Simon et al, 2005) . In these studies, however, the total beta-catenin level was analyzed only by immunoblot analysis. Beta-catenin is expressed not only as nuclear NPBC but also as a cadherin-associated protein in the inner cytomembrane (Conacci-Sorrell et al, 2002) . The present study found that normal erythroblasts expressed cytoplasmic or membrane-associated beta-catenin but not nuclear NPBC (Fig 1A) . Both membrane-associated and nuclear beta-catenin was expressed in malignant erythroblasts in subtype M6
(A) (B) ( Fig 1A) . These findings suggest that increased nuclear NPBC levels were the result of aberrant signal transduction in the Wnt pathway or an abnormality of beta-catenin itself. In this study, the expression levels of total and non-phosphorylated beta-catenin were correlated but varied significantly among leukemia samples. In M6 and M7 samples, the expression of beta-catenin was significantly augmented, whereas it was hardly detected in M3 and normal BM samples. These variations suggest the possibility that Wnt/beta-catenin signaling is mediated by multiple factors, such as immaturity, lineage, and oncogenic signals.
We established a correlation between nuclear NPBC + and poor survival in AML patients. The prognostic value of total beta-catenin expression has been previously studied in AML patients (Ysebaert et al, 2006) , but the present study clearly showed for the first time that nuclear NPBC is associated with prognosis. The association was still observed even if M6/M7 and/or M3 patients were excluded from the analysis. Nuclear NPBC might be a new prognostic marker for AML and MDS that can be evaluated by histopathological examination.
Wnts are a family of paracrine and autocrine factors that regulate cell growth and cell fate . The Wnt autocrine signaling mechanism was initially discovered in human breast and ovarian tumor cell lines as well as in MM primary samples (Bafico et al, 2004; Derksen et al, 2004) . Since several Wnt family members have been reported in BM stromal cells, it is possible that leukaemia cells respond to different proteins of the Wnt/beta-catenin pathway secreted by stromal cells in a paracrine fashion (Austin et al, 1997; Van Den Berg et al, 1998; Etheridge et al, 2004) . Nuclear NPBC was detected in some cell lines only when they were transplanted in non-obese diabetic/severe combined immunodeficient/gammacnull (NOG) mice (data not shown). Thus, the leukaemia niche may have an important role in nuclear NPBC expression during AML.
MDS is a clonal hematopoietic stem cell disorder characterized by multi-lineage dysplasia and pancytopenia in which further genetic events may be required for the rapid expansion of leukaemic blasts (Heaney & Golde, 1999; Hirai, 2003) . Although nuclear NPBC has been studied in many cancers as well as haematological malignancies, it has not been studied in MDS (Morin et al, 1997; Barker & Clevers, 2000; Giles et al, 2003) . This is the first study to report the expression of betacatenin in MDS patients. Here we showed that nuclear NPBC was related to the IPSS score and that secondary AML from MDS showed the highest percentage of nuclear NPBC expression. The Wnt signaling pathway may play an important role in the pathogenesis of the transformation of MDS into AML. Regarding chromosomal abnormalities, )7/)7q and/or complex karyotypes were significantly associated with the presence of nuclear NPBC. According to recent data (Liu et al, 2006) , the gene encoding alpha-catenin (CTNNA1) is suppressed by deletion and/or methylation. Both alpha-catenin and beta-catenin bind to the inner membrane of hematopoietic cells, and cadherin binds to actin filaments via the catenin complex. If the expression of alpha-catenin is suppressed in the 5q-genotype or for other reasons, beta-catenin may be abnormally located or activated. In this study, abnormalities of chromosome 5 were associated with the presence of NPBC but this was not statistically significant. The reason why NPBC is associated with chromosome 7 abnormalities remains unclear.
A gene encoded by chromosome 7 may be associated with the regulation of the Wnt/beta-catenin pathway. Several possible candidate genes including SFRP4, WNT2, and FZD1 and FZD9 are located at human chromosome 7. There are reports that sFRP4 plays a role in tumor suppression via the Wnt pathway (Hrzenjak et al, 2004; Horvath et al, 2007) , although the specific relationship remains unknown. Since many molecules are directly or indirectly associated with the phosphorylation, stabilization and nuclear translocation of beta-catenin, the presence of nuclear NPBC might provide a clue to find a new leukemia-associated signaling mechanism.
In conclusion, in situ detection of nuclear NPBC by immunohistochemistry of paraffin sections from BM specimens could be used to predict the prognosis of AML and MDS. Understanding the mechanisms leading to leukemogenesis in nuclear NPBC + AML and MDS may lead to new anti-leukemia therapies.
